NovaBridge Biosciences NBP

NovaBridge Biosciences is a global biotechnology platform company focused on the discovery and development of innovative therapeutics for oncology and ophthalmology. The company leverages its internal research capabilities and strategic collaborations to advance a pipeline of bispecific antibodies, including its lead candidate gavastomig targeting Claudin 18.2 and 4 1BB for gastric and other gastrointestinal cancers, as well as uliledlimab targeting CD73, ragistomig targeting PD L1 and 4 1BB, and VIS 101 targeting VEGF A and ANG 2 for wet age related macular degeneration and diabetic macular edema. Gavastomig is currently being evaluated in a global phase two study combined with nivolumab and chemotherapy for first line metastatic gastric cancer, while uliledlimab development has been paused pending further data from a partner sponsored study in China. Ragistomig is being investigated in a phase one trial by its collaboration partner ABL Bio across multiple solid tumor types. VIS 101 has completed phase one trials and is preparing for a phase two b study in wet age related macular degeneration. Through these programs, NovaBridge aims to bring differentiated treatments to patients with high unmet medical need.

NovaBridge currently generates revenue through licensing agreements, collaboration arrangements, and milestone payments associated with its therapeutic candidates. The company has entered into several licensing deals, such as the upfront payment of $5 million to AffaMed for rights to VIS 101 outside certain Asian territories and the $7 million payment to AskGene for an exclusive license in those territories, which also includes reimbursement of development costs. Additionally, collaborations with partners like Bristol Myers Squibb provide clinical trial support and potential future milestones, while agreements with ABL Bio govern joint development of gavastomig and ragistomig under shared worldwide rights excluding Greater China and South Korea. The company also receives financing from strategic investors, which although not classified as operating revenue, supports ongoing research and development activities. While the company has not yet commercialized any product, these agreements constitute its primary source of revenue.

Within the biotechnology sector, NovaBridge occupies a niche focused on bispecific antibody therapeutics that engage dual targets to enhance efficacy while limiting systemic toxicity. Its lead oncology asset, gavastomig, competes with approved agents such as Zolbetuximab (Astellas) and other Claudin 18.2 directed therapies in development from companies like AstraZeneca, Transcenta, and Sino Biopharmaceuticals. In ophthalmology, VIS 101 faces competition from established VEGF inhibitors like aflibercept (Regeneron) and the bispecific faricimab (Roche), but claims advantages in durability and dosing frequency that may allow less frequent administration. The company’s competitive strengths lie in its proprietary bispecific designs that conditionally activate immune stimuli only upon tumor antigen engagement, thereby reducing off target effects, and in its ability to secure global rights through partnerships with ABL Bio and other collaborators. Additionally, NovaBridge benefits from a diversified pipeline that addresses multiple high unmet medical needs, reducing reliance on any single asset and providing flexibility to allocate resources based on clinical progress.

NovaBridge’s prospective customers include hospitals, oncology clinics, and ophthalmology centers that would administer its therapies to patients once approved. The company also engages with research institutions and clinical trial sites for study execution, collaborating with investigators who specialize in gastric cancer, colorectal cancer, and retinal diseases. Although no specific customer names are disclosed in the filing, the target market comprises healthcare providers treating gastric, gastroesophageal, pancreatic, and biliary cancers, as well as patients with wet age related macular degeneration and diabetic macular edema. These providers range from academic medical centers to community oncology practices and specialized retina clinics, reflecting the broad clinical settings where NovaBridge’s therapies could be used if they receive regulatory approval.